Old worming drug shows promise against tough prostate cancer
NCT ID NCT03123978
First seen May 14, 2026 · Last updated May 14, 2026
Summary
This early-stage trial tested a combination of two drugs—enzalutamide, a standard hormone therapy, and niclosamide, a drug usually used for tapeworm infections—in 6 men with castration-resistant prostate cancer that had spread or returned. The goal was to find the safest dose and identify side effects. The study was completed but did not report major breakthroughs, and patients still require ongoing treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC PROSTATE CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of California Davis Comprehensive Cancer Center
Sacramento, California, 95817, United States
Conditions
Explore the condition pages connected to this study.